3,4-Dimethoxybenzaldehyde

3,4-Dimethoxybenzaldehyde

SCHEMBL2529644

[2H]C(=O)c1ccc(OC([2H])([2H])[2H])c(OC([2H])([2H])[2H])c1

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.55
TSHR P16473 1/20 0.55
FDPS P14324 1/20 0.43
APP P05067 1/20 0.43
GAA P10253 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
MAPK1 P28482 2/20 0.42
KDM4E B2RXH2 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CYP1A1 P04798 4/20 0.42
CYP1B1 Q16678 3/20 0.42
TUBB4A P04350 1/20 0.42
TUBB P07437 1/20 0.42
TUBA3C P0DPH7 1/20 0.42
TUBA1B P68363 1/20 0.42
TUBA4A P68366 1/20 0.42
TUBB4B P68371 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
3,4-Dimethoxybenzaldehyde SCHEMBL2370925 0.86 ALDH1A1 (0.74) ALDH1A1TSHRFDPSGAATDP1
SCHEMBL704683 0.84 ALDH1A1 (0.40) ALDH1A1TSHRFDPSAPPKDM4E
3,4-Dimethoxybenzaldehyde SCHEMBL2370931 0.83 ALDH1A1 (0.81) ALDH1A1TSHRFDPSGAATDP1
3,4-Dimethoxybenzaldehyde SCHEMBL13290624 0.83 ALDH1A1 (0.81) ALDH1A1TSHRFDPSGAATDP1
SCHEMBL12055850 0.75 VCP (0.51) ALDH1A1TSHRAPPGAATDP1
SCHEMBL17370918 0.74 JUN (0.66) ALDH1A1TSHRGAATDP1KDM4E
SCHEMBL703866 0.74 ALDH1A1 (0.62) ALDH1A1TSHRFDPSGAATDP1
SCHEMBL4146797 0.73 VCP (0.79) ALDH1A1TDP1MAPK1KDM4ESMN1; SMN2
SCHEMBL15580939 0.72 ALDH1A1 (0.53) ALDH1A1TSHRFDPSTDP1KDM4E
Vanillin SCHEMBL29420568 0.72 ALDH1A1 (0.73) ALDH1A1TSHRAPPGAATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575221-B2 Derivatives of dimethylcurcumin CONCERT PHARMACEUTICALS, INC. (US) 2013-11-05 US disclosed
US-8084464-B2 Tetrahydroisoquinoline derivatives CONCERT PHARMACEUTICALS, INC. (US) 2011-12-27 US disclosed
US-20110257271-A1 DERIVATIVES OF DIMETHYLCURCUMIN CONCERT PHARMACEUTICALS, INC. 2011-10-20 US disclosed
US-20090192188-A1 TETRAHYDROISOQUINOLINE DERIVATIVES SUN PHARMACEUTICAL INDUSTRIES, INC. 2009-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192188-A1 TETRAHYDROISOQUINOLINE DERIVATIVES HCRTR2, HCRTR1, OXTR ALDH1A1 1612/4885TSHR 932/4885FDPS 4517/4885
US-20110257271-A1 DERIVATIVES OF DIMETHYLCURCUMIN UROD, UGT1A1, UGT1A3 ALDH1A1 319/4885TSHR 4266/4885FDPS 153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.